Biosyngen
Manufacturing · Singapore · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5 Tai Seng Avenue #08-51, Hougang, North...Phone Number
+65 68088550Website
www.biosyngen.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Biosyngen
Biosyngen is a global leader in cell therapy, specializing in the design of cutting-edge immunotherapies aimed at providing optimal treatment options for patients. The company focuses on developing first-in-class products targeting solid tumors, utilizing proven technologies such as CAR-T and TIL. With a robust pipeline and proprietary technology platforms, Biosyngen is well-positioned to address unmet needs in oncology. Their global strategy includes partnerships with top scientific research institutions and a scalable GMP production capability to serve patients worldwide.Explore more
Biosyngen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biosyngen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Biosyngen has recently received funding, and reach out quickly before it becomes old news!
Click to see if Biosyngen had a recent Job posting/layoffs
Product Launch: Get notified when Biosyngen launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Biosyngen has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Biosyngen recently announced quarterly report
Check out if Biosyngen is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Biosyngen
Biosyngen, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Biosyngen
Find 3 more new buyers
Company Profile Activity
Activity Insights
Biosyngen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Biosyngen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Biosyngen.
Biosyngen Tech Stack
A closer look at the technologies used by Biosyngen
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Project
Research & Development, Intellectual Property, Legal Affairs, Medical Research
Project
Product Development, Research & Development, Legal Affairs
Project
Biosyngen News & Media
Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting
BARCELONA, Spain, Sept. 20, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place from September 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings...Biosyngen Presents Pioneering"Conditional Activation + Armor Enhancement" SUPER-T technology at ESMO 2024
BARCELONA, Spain, Sept. 19, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place from September 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings...Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress
BARCELONA, Spain, Sept. 18, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and researchers from around the globe, showcasing the latest advancements in the field and providing high-quality educational and networking opportunities for oncology professionals. Biosyngen, an innovative biBiosyngen's BRG01 Receives FDA Approval for Phase II Clinical Trial
SINGAPORE, Aug. 13, 2024 /PRNewswire/ -- Biosyngen is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with a pivotal Phase lI clinical trial. This marks the first cell therapy to enter Phase lI trials in both the U.S. and China for the treatment of relapsed/metastatic EBV-positive nasopharyngeal carcinoma, demonstrating a breakthrough in solid tumor treatment. The Center for Drug Evaluation (CDE)
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Biosyngen
Sign Up For FreeTo access detailed company insights
Biosyngen is a global leader in cell therapy, specializing in the design of cutting-edge immunotherapies aimed at providing optimal treatment options for patients. The company focuses on developing first-in-class products targeting solid tumors, utilizing proven technologies such as CAR-T and TIL. With a robust pipeline and proprietary technology p... Read More
